跳至主要内容
临床试验/NCT02937181
NCT02937181Unknown4 期

Antibiotic Prophylaxis With Ceftaroline for Type II and II Open Fractures: a Phase 4, Open-label, Prospective Clinical Trial

Olayemi Osiyemi MD1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
50
试验地点
1
主要终点
Rate of fracture site infection at 30 days between ceftaroline and historical hospital rate

研究概览

简要总结

Prospective look at antibiotic prophylaxis with Ceftaroline in patients with type II and III open fractures

详细描述

Determine if antibiotic prophylaxis with Ceftaroline in patients with type II and III open fractures is a safe and effective alternative to standard combination therapy

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female >= 18 years old
  • complete an informed consent
  • patients are diagnosed with a type II or III open fracture

排除标准

  • allergy to beta-lactam antibiotics prior to screening
  • prior to enrollment: patients received 3 or more doses of antibiotic prophylaxis
  • pregnant female
  • inability to provide consent

研究组 & 干预措施

open fractures type II and III

Experimental

Every patients will receive Ceftaroline in an open label, single arm

干预措施: Ceftaroline (Drug)

结局指标

主要结局

Rate of fracture site infection at 30 days between ceftaroline and historical hospital rate

时间窗: 30 days

次要结局

  • Incidence of acute kidney injury(30 days)

研究者

发起方
Olayemi Osiyemi MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Olayemi Osiyemi MD

President/

Triple O Research Institute PA

研究点 (1)

Loading locations...

相似试验

Antibiotic Prophylaxis in Open Fractures | 临床试验